As of 2026-04-03, the Relative Valuation of Pacific Biosciences of California Inc (PACB) is (41.48) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.34 USD, the upside of Pacific Biosciences of California Inc based on Relative Valuation is -3195.2%.
The range of the Relative Valuation is (39.26) - (42.66) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.7x - 26.1x | 24.1x |
| Forward P/E multiples | 20.2x - 23.6x | 21.8x |
| Fair Price | (39.26) - (42.66) | (41.48) |
| Upside | -3029.8% - -3283.6% | -3195.2% |
| Date | P/E |
| 2026-04-01 | -0.75 |
| 2026-03-31 | -0.73 |
| 2026-03-30 | -0.70 |
| 2026-03-27 | -0.70 |
| 2026-03-26 | -0.75 |
| 2026-03-25 | -0.77 |
| 2026-03-24 | -0.77 |
| 2026-03-23 | -0.77 |
| 2026-03-20 | -0.74 |
| 2026-03-19 | -0.77 |
| 2026-03-18 | -0.74 |
| 2026-03-17 | -0.76 |
| 2026-03-16 | -0.75 |
| 2026-03-13 | -0.74 |
| 2026-03-12 | -0.70 |
| 2026-03-11 | -0.75 |
| 2026-03-10 | -0.76 |
| 2026-03-09 | -0.77 |
| 2026-03-06 | -0.76 |
| 2026-03-05 | -0.84 |
| 2026-03-04 | -0.86 |
| 2026-03-03 | -0.84 |
| 2026-03-02 | -0.90 |
| 2026-02-27 | -0.93 |
| 2026-02-26 | -0.98 |
| 2026-02-25 | -0.90 |
| 2026-02-24 | -0.92 |
| 2026-02-23 | -0.87 |
| 2026-02-20 | -0.89 |
| 2026-02-19 | -0.93 |
| 2026-02-18 | -0.90 |
| 2026-02-17 | -0.87 |
| 2026-02-13 | -0.95 |
| 2026-02-12 | -1.02 |
| 2026-02-11 | -1.02 |
| 2026-02-10 | -1.00 |
| 2026-02-09 | -1.02 |
| 2026-02-06 | -1.01 |
| 2026-02-05 | -0.95 |
| 2026-02-04 | -1.08 |
| 2026-02-03 | -1.13 |
| 2026-02-02 | -1.14 |
| 2026-01-30 | -1.25 |
| 2026-01-29 | -1.31 |
| 2026-01-28 | -1.32 |
| 2026-01-27 | -1.42 |
| 2026-01-26 | -1.39 |
| 2026-01-23 | -1.43 |
| 2026-01-22 | -1.48 |
| 2026-01-21 | -1.34 |